ReEmerge announced a $37 million Series A on September 15, 2026, to develop brain stimulation for persistent cognitive impairment after traumatic brain injury. The next step is testing the approach in more patients.
What the money is for
The announcement published by investor 415 Capital names U.S. Venture Partners and Santé as co-leads. Proceeds will support clinical testing, technology development and regulatory work.
The company's Cognitive Network Restoration Therapy targets networks involving the central thalamus, a region connected to attention and arousal. It aims to activate circuits that remain viable but function poorly following injury. This is a treatment-development hypothesis, rather than an outcome established by the financing.
The earlier human evidence
A 2023 phase 1 feasibility study in Nature Medicine tested central thalamic deep brain stimulation in six people with moderate-to-severe traumatic brain injury. Their injuries had occurred three to 18 years earlier. Electrode placement was guided by individual brain imaging and modeling.
Five participants completed the treatment assessment. They improved on a timed test involving executive control after a three-month stimulation period. This is encouraging because the work examined difficulties that had persisted for years. It remains a small study in a selected group, rather than a reliable estimate of how most people with brain injury would respond.
The risks belong in the same story
Weill Cornell Medicine's account reports that one participant developed a scalp infection, had the electrodes removed and withdrew. The remaining five received stimulation for 12 hours each day during the treatment window.
These details matter. An implanted system has a different burden from software or an external wearable. The benefits, surgical risks, programming requirements and long-term care all need to be considered together.
What to watch next
The meaningful next milestone is a clearly reported clinical study: who qualified, how outcomes were measured, how long improvements lasted and what adverse events occurred. A faster test score and an easier return to everyday activities are related questions, but they are not interchangeable.
It will also be important to report who did not benefit. A study that explains the limits of a treatment gives patients and clinicians more useful information than a success story without a denominator.
Our reading of this financing is that investors are supporting the move from an early research signal toward a more complete treatment assessment. The amount raised tells us about resources and expectations. The clinical work will tell us whether those expectations translate into useful care for the people the treatment is intended to serve.